Covid: A game changer?, page-5

Let’s not forget the sub study for Covid which was tacked on to HIV… no mentions on this front or disclosure on results. However Biotron was upbeat in 2022 on a “speedy” LMAO pathway…

“The sub-study provides a speedy and cost effective pathway to explore the potential benefit of BIT225 against SARS-CoV-2 in a high-risk patient population. We look forward to completing the study and reporting results in mid-2023.”

… have a nice hot cuppa while MM dangles her yarn round those needles in preparation for an intricate tea cosy to get us through this winter. Don’t you shareholders dare ask where results are to the sub study. You have no right, she is only earning $400k + of your money… and always remember biotech is a very very very long road… there will be bumps in coming weeks or an imminent donut or two.